[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:pik3ca-related-overgrowth-spectrum":3},{"name":4,"total":5,"trials":6,"biomarkers":27,"states":28},"PIK3CA-Related Overgrowth Spectrum",3,[7,14,21],{"nct_id":8,"title":9,"phases":10,"status":11,"updated_at":12,"content_modified":13},"NCT00001403","Study of Proteus Syndrome and Related Congenital Disorders",[],"RECRUITING","2026-08-03T00:52:17.025445Z","2026-07-05T18:42:10.721289Z",{"nct_id":15,"title":16,"phases":17,"status":11,"updated_at":19,"content_modified":20},"NCT06789913","A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation (The ReInspire Study)",[18],"Phase 2","2026-08-03T00:58:57.291114Z","2026-07-05T05:32:16.695791Z",{"nct_id":22,"title":23,"phases":24,"status":11,"updated_at":25,"content_modified":26},"NCT06997588","EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS)",[18],"2026-08-03T03:11:37.958805Z","2026-05-05T02:35:31.765926Z",[],[]]